Found: 3
Select item for more details and to access through your institution.
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.
- Published in:
- Experimental Hematology & Oncology, 2019, v. 8, n. 1, p. N.PAG, doi. 10.1186/s40164-019-0133-1
- By:
- Publication type:
- Article
Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 2, p. 331, doi. 10.1007/s00432-021-03827-9
- By:
- Publication type:
- Article
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. N.PAG, doi. 10.1038/s41467-020-18372-1
- By:
- Publication type:
- Article